Rs 10,000 and a Garage: How Kiran Mazumdar-Shaw Built Biocon, and Who Takes It Next

From Master Brewer to Garage Biotech

In 1975, Kiran Mazumdar-Shaw finished a master-brewer degree at Ballarat College, part of Melbourne University. According to her reference biography, she had topped the class the year before, as the only woman on the course. She had studied zoology at Bangalore University, graduating in 1973, and brewing was meant to be her profession. It turned out to be the doorway to something else.

In 1978 she started Biocon India in the garage of her rented home in Bengaluru, with seed capital of Rs 10,000. Indian law then capped foreign ownership of the joint venture at 30%, which left her with the other 70%. Her first employee was a retired garage mechanic. The business made enzymes, and within a year it was exporting them to the United States and Europe.

Climbing the Value Chain: From Enzymes to Complex Biologics

Biocon's own history, as summarised on its company page, reads as a steady climb up the value chain. In 2001 it became the first Indian company approved by the US Food and Drug Administration to make lovastatin, a cholesterol drug. In 2003 it was reported as the first company in the world to develop human insulin on a Pichia expression system. In 2006 it launched BIOMAb EGFR, described as India's first home-grown humanised monoclonal antibody, for head-and-neck cancer. A first biosimilar, CANMAb, followed in 2014, and in 2016 it became the first Indian company to launch a biosimilar insulin glargine pen in Japan. In 2017 the US regulator approved a trastuzumab biosimilar developed with Mylan, and in 2018 the European Commission approved biosimilar insulin glargine.

“Claire will transition into my role at the right time so not planning to hang up my boots just yet!!”

Scale, Spinoffs and Global Biologics Expansion

The business side matured alongside the science. Biocon's 2004 public offering was oversubscribed about 33 times, and the company crossed a US$1 billion valuation on its first day of trading. It spun out Syngene, a contract research and manufacturing arm that listed in 2015. In 2021 it sold 15% of Biocon Biologics to Serum Institute of India at a stated valuation of US$4.9 billion, and in 2022 Biocon Biologics acquired Viatris's biosimilars business for roughly US$3.3 billion.

In the financial year to March 2025, the company's reference page reports revenue of Rs 16,470 crore and net income of Rs 1,013 crore. The company says it serves patients in more than 120 countries.

Honours, Philanthropy and the Giving Pledge

Her honours cover business, science and public service: the Padma Shri (1989) and Padma Bhushan (2005); the Othmer Gold Medal (2014); the Nikkei Asia Prize (2009); EY World Entrepreneur of the Year (2020); and in January 2020 Australia's highest civilian honour. In 2019 she was elected to the US National Academy of Engineering, reported as a first for an Indian woman. In 2014 she became the first woman to chair the board of governors of IIM Bangalore. In 2015 she joined The Giving Pledge, committing to give away at least half her wealth, and the Biocon Foundation, launched in 2004, runs health and community programmes.

The 2026 Succession Announcement & Founder Lessons

In May 2026, Entrepreneur India reported that she had named her niece, Claire Mazumdar, as her eventual successor. On X she wrote: "Claire will transition into my role at the right time so not planning to hang up my boots just yet!!" Claire, 37, is founding CEO of Bicara Therapeutics, a Biocon-incubated cancer-drug company that listed publicly in 2024. She holds a biological engineering degree from MIT and an MBA and a PhD in cancer biology from Stanford. The report gave no handover date. Founders of family-linked companies often leave succession unspoken. Making it public gives investors, employees and partners a long runway and keeps the choice from becoming a surprise.

What founders can take from her story: 1. Start small, and ship. Rs 10,000 and a garage proved less important than getting the first export. 2. Work the constraint. The foreign-ownership cap shaped the structure; she built the company around it. 3. Climb the value chain deliberately. Enzymes, then generics, then biosimilars, then complex biologics, each step needing new science and new regulators. 4. Plan the handover while you still lead. A named, qualified successor and an open timetable calm everyone.

Independent editorial profile built from public sources. We have not interviewed Ms Mazumdar-Shaw.